The company, which develops software services for drug commercialization, announced the opening of its offices in Singapore and Mumbai, with the concurrent appointment of a regional leadership team which will be based in Singapore.
Additionally, Eversana announced plans to open offices in Shanghai and Tokyo by the end of 2019, along with an intention to invest ‘significant’ capital resources to build its regional footprint.
According to the company, this move answers an increased need for global solution capabilities for companies headquartered in Asia, as well as US and European headquartered companies looking to bring solutions to the Asian markets.
Jim Lang, CEO of Eversana, commented in a statement that China and Japan are now the second and third largest life sciences markets and “are widely regarded as vital contributors to the future of precision medicine.”
The company already has offices in 25 locations across North America, Europe and Asia, and employs more than 2,000 people.
Eversana also recently announced an agreement to adopt Cryoport’s cold chain logistics services for regenerative medicines.
